antichymotrypsin, and a free or unbound form which is probably an inactive zymogen.~,6 Most of the literature on the use of PSA is based on the Pros-Check" polyclonal RIA (Yang Laboratories) and the Hybritech TANDE~-R monoclonal immunoradiometric assay (IRMA).I The Hybritech assay in IRMA, enzymeimmunoassay (EIA) and fluoroimmunoassay (FIA) form (as used in the Baxter-Dade Stratus" analyser) is by far the most widely used in this country and has become a de facto standard for PSA assays. We have compared our Hybritech TANDEMoo-E EIA with the Roche" Core PSA EIA with particular reference to overall assay bias and the differential reactivity to free and bound forms of PSA in serum.
Methods

PSA assays
The Roche PSA assay is a one-step EIA with two different mouse monoclonal antibodies, one coupled to a bead and the other to horseradish peroxidase with tetramethyl benzidine substrate. It was performed on the Roche Cobas" Core automated random continuous access bead EIA analyser, according to the manufacturer's instructions. Roche calibration and quality control material is supplied with the kits and this was used throughout. The Hybritech TANDEM'l-E EIA is a one step, two site assay using two different mouse monoclonals, one coupled to a bead and the other to alkaline phosphatase, with pnitrophenyl phosphate substrate. It was performed manually according to the manufacturer's instructions using supplied calibrators and quality control samples and read on the PHOTON-II analyser.
a-I antichymotrypsin assay
These were performed using an in-house immunoturbidimetric method on the Roche Cobas" Mira S with calibrators and rabbit anti-human o-I antichymotrypsin from DAKO (High Wycombe, UK).
Separation of PSA fractions
Free and bound forms of PSA from serum of patients with prostatic carcinoma were obtained by gel filtration on a 26 x 400 mm C-column system using Sephacryl S-IOO HR (Pharmacia-LKB, UK) in phosphate buffered saline (pH 7· 3, 0'15 M, 1= 0,165). The column was calibrated with horse cytochrome c (M, 124(0), bovine carbonic anhydrase (M, 29000) and yeast alcohol dehydrogenase (M, 150000) from Sigma UK. The effect of dilution of samples by the column buffer (Phosphate-Buffered Saline) on each assay was tested by serial dilution of three patient samples with high PSA values (but within the assay range) for each assay.
concentrations of the Hybritech assay (F-ratio for variances = 1· 83 for 13 and 183 d.f.). Graphical comparison of 50 samples from patients with prostate carcinoma, with values within the analytical range of both assays, showed evidence for a dependence of the analytical error on PSA concentration (heteroscedasticity) in the assay results which was mostly corrected by log transformation." There was a significant degree of bias between the two assays, the Roche assay giving values lower on average than the Hybritech assay. Application of the Passing and Bablok non-parametric linear regression (which assumes similar levels of error in both variables) to the comparison results (y = a + bx; y = Roche assay; x= Hybritech assay) showed a significant deviation of the slope (b) from unity (b=0'9; 95070 CI O' 82 to O' 94), and a small but significant deviation of the intercept (a) from zero [(a=-1'45; 95070 CI -0,23 to -0'36) Fig. 1 ]. A Bland-Altman analysis of the data to obtain a single measure of agreement between the two assays confirmed a high degree of heteroscedasticity in the results and an estimate of the agreement was obtained after log transformation of the results (Fig. 2 ). The mean proportional bias of the Roche assay to the Hybritech assay by this method was higher than that estimated by regression at 0·75 (i.e. the Roche assay was on average 25070 lower than the Hybritech assay) and this was statistically significant from zero with a 95070 CI for the mean of 0'83 to 0·69; the overall 95070 limits of agreement were 1·43 to 0·4 (i.e. the Roche assay
Statistical analysis
Data were compared using the non-parametric linear regression of Passing and Bablok 7 and the measurement of agreement and graphical technique of Bland and Altman." Dilution effects were assessed by linear regression using Systat® for Windows" (Systat UK; West Wycombe, UK).
RESULTS AND DISCUSSION
,.,
The assays have similar claimed performance characteristics with similar limits of detection, imprecisions and assay ranges. We found the Hybritech assay to have between batch (overall) imprecisions of 12·9070 at 4 ng/mL (n = 184) and 6·3070 at 68 ng/mL (n = 167) and the Roche assay 3·9070 at 9'8ng/mL (n=14), which is not significantly different from the imprecision at low assay in the two serums studied were quite different (Table I) and there was a significant difference between the mean proportional bias for the free and bound peaks in patient No.2 and the pooled data ( Table 2) the Roche assay giving an average response 2·6 times higher than the Hybritech assay for free PSA in the samples examined. Dilution of high PSA serums (ranging from 85 to 41 ng/mL) in column buffer showed no significant deviations from the expected result up to a dilution of one in 128 (Fig. 5) ; the slope of observed PSA (y) on expected PSA (x), was 1'001, 1'003, and 1·006 for each specimen determined by the Roche assay with standard errors of 0'001,0'003 and 0'006, respectively; 
could be as much as 43070 higher to 60070 lower than the Hybritech assay on an individual patient). Gel filtration of serums with high PSA values revealed two peaks of PSA activity, a high M, peak eluting at 115000-142000 (mean 128000; n = 3) corresponding to the protein bound peak of PSA, and a low M, peak at 29000-36000 (mean 32000; n = 3), corresponding to the free PSA zymogen peak (Fig. 3) . Assay of o-I antichymotrypsin on the column fractions showed two peaks at 108000-114000, one just after the complexed PSA peak, and another almost in the void volume. The low M, PSA peak corresponds to that found by others but the complexed peak seems to be a little higher than the expected 101000 for an a-I antichymotrypsin-PSA complex 5, 6 as does the first o-I antichymotrypsin peak. We cannot explain this but other authors have found a M, of 150000 for the complexed form.!? It may be that a lot of the a-I anti chymotrypsin in these samples was itself multimeric or complexed which would elevate the average M, of the PSA complex.
A comparison of the assays on separated fractions of free and bound PSA showed a high degree of differential reactivity. Results on the first (bound) PSA peak were similar to the results of the total activity, the Roche giving slightly lower values than the Hybritech assay, but the results on the second (free) peak were markedly different, the Hybritech assay giving much lower values than the Roche assay (Fig. 4) . The proportions of free and bound estimated by each -03 .. Expected PSA("!l/mL) 
CONCLUSIONS
There is a small but significant measure of disagreement between the Hybritech and Roche assays when measuring total serum PSA. The bias is predominantly proportional with the Roche assay giving results 10-25070 lower than the Hybritech assay, depending on the method used to assess it. However, the Roche assay appears to be much more sensitive to the free PSA fraction in serum than the Hybritech assay and gives a completely different bias when compared to the complexed form. Our sample is small, but the results are unequivocal. Their responses to the complexed serum fraction are much more similar to each other and to the response to the total serum PSA, perhaps because the complexed fraction is present in the highest concentrations in the samples; the concentration of the free fraction can form from 7-50% of the total serum PSA activity in prostate cancer patients" so it is quite clear that there will be serious disagreement between total PSA assays unless their reactivity to both forms is more clearly defined. Graves et al," have shown that the use of a common PSA standard for the Hybritech and Pros-Check" for the Hybritech assay slopes were 1· 007, 1· 009, 1·027 with standard errors of 0'039,0'038 and O' 094, respectively (n = 8 for all dilution series).
We think it unlikely that matrix effects were responsible for these results. assays improves the agreement between assays, and this is undoubtedly an important factor; but if the difference in response to the free and complexed forms of PSA seen here is representative of the likely differences in antibody reactivity to be encountered in other commercial assays, then this problem is equally if not more important. An analogous situation has been found for {i-HCG where differences in antibody reactivity to free and a-bound subunits, {i-subunit fragments, molecules with different carbohydrate content and 'nicks' in the molecule have been shown to produce discordance in results between assays." There are 'nicks' in the PSA molecule! which may influence reactivity, but this possibility has not been specifically tested as yet. A further confounding factor for PSA is the possibility of cross-reaction with kallikrein from various sources, which have a 61-7711/0 amino-acid homology with the PSA molecule.P If there is likely to be any clinical value in the relative proportions of the free and complexed PSA in serum, as claimed for the improved diagnostic sensitivity of an assay of the complexed form in prostate cancer,' then separate assays and calibration of each form will be required to fully assess both this and the full utility and accuracy of PSA assays as tumour markers.
